Description
Cyclobenzaprine is a centrally acting muscle relaxant. It does not work at the muscle itself but in the brainstem, where it dampens tonic somatic motor activity. Structurally it is closely related to the tricyclic antidepressants. That heritage explains most of its profile: the sedation, the anticholinergic effects and the interactions listed further down.
The immediate-release form is taken three times a day at 10mg. That is exactly where its best-known problem comes from: levels spike three times a day. Sedation follows those peaks. The extended-release form solves this through formulation. The study by Darwish and colleagues compared a single 30mg extended-release dose against three 10mg immediate-release doses in 18 healthy volunteers and found comparable overall exposure with a completely different shape: a single flat peak at around six hours versus an up-and-down pattern across the whole day.
The review by Darwish and Hellriegel fills in the rest of the pharmacokinetics. Levels are sustained over 24 hours and steady state is reached by day seven. The 30mg capsule delivers roughly twice the exposure of the 15mg capsule. Two points matter in practice. Food increases absorption. Exposure is also higher in older subjects.
The efficacy data come from two identically designed randomised, double-blind, placebo- and active-controlled trials reported by Malanga and colleagues. They enrolled just over 500 patients with muscle spasm associated with acute neck or back pain, randomised for 14 days to 15mg extended release, 30mg extended release, 10mg immediate release three times daily, or placebo. The primary endpoint was the patient’s own rating at day four. Both extended-release doses beat placebo significantly there. The 30mg dose additionally showed benefits in pain relief and restriction of movement. The finding that matters most day to day is a different one: daytime drowsiness was reported less often in the extended-release groups than on the immediate-release form.
Unlike carisoprodol, which is a controlled substance in many countries, cyclobenzaprine usually falls outside narcotics legislation. Within this drug group that makes it the less complicated option.
You can order Cyclobenzaprine ER as extended-release tablets with 15mg per tablet, 10 tablets per blister.
This information is for research and educational purposes only. No medical advice.
Risks & Safety
The tricyclic backbone is the thread running through almost every point here.
- MAO inhibitors are an absolute contraindication: The combination can cause hypertensive crisis, seizures and serotonin syndrome. At least 14 days belong between stopping an MAO inhibitor and starting cyclobenzaprine.
- Serotonergic agents: Together with SSRIs, SNRIs, tramadol or triptans the risk of serotonin syndrome rises. Agitation, fever, muscle twitching and a racing pulse are the signs that count.
- Sedation: The most common adverse effect in every trial cited here. Driving and machinery are out until you know how strongly it hits you. Alcohol and other depressants add to it.
- Anticholinergic effects: Dry mouth, blurred vision, constipation, urinary retention. In narrow-angle glaucoma, prostate enlargement and urinary retention that is not a side note but a problem.
- Cardiac: Caution applies after recent infarction, with arrhythmias, conduction disturbance and heart failure. The same applies in hyperthyroidism.
- Older people: Exposure is higher according to Darwish and Hellriegel. Combined with sedation and anticholinergic effects, that mainly means an increased risk of falls.
- A short-term agent: The benefit is documented in these trials for two weeks of treatment, not for continuous use.
- Food increases absorption: Taking the capsule fasted one day and with a meal the next gives you different levels.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Cyclobenzaprine ER for muscle spasm associated with low back and neck pain - Current Medical Research and Opinion 2009, Malanga et al: two identically designed randomised, double-blind, placebo- and active-controlled trials in just over 500 patients. Both 15mg and 30mg extended release beat placebo significantly at day four. Daytime drowsiness occurred less often than on the immediate-release form.
- Pharmacokinetic profile of once-daily cyclobenzaprine extended-release - Expert Opinion on Drug Metabolism and Toxicology 2010, Darwish and Hellriegel: review of four pharmacokinetic studies, with levels sustained over 24 hours, steady state by day seven and higher exposure with food and in older subjects.
- Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily - Clinical Drug Investigation 2008, Darwish et al: crossover study in 18 healthy adults with comparable overall exposure for both forms, but a single peak at around six hours instead of several spikes across the day.
